Trial reportAtherosclerosis2013
The Effect of Lipid Modification on Peripheral Artery Disease after Endovascular Intervention Trial (ELIMIT).
Trial report in Atherosclerosis, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00687076 (Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention), which is not on this map. Cited by 17 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Lipid Modification on Peripheral Arterial Disease After Endovascular Intervention ("The ELIMIT Trial")
Who cites it
17 citing papers in PubMed, 5 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- The adverse effects of oral niacin/nicotinamide - an overview of reviews.Eye (London, England) · 2025Pooled it
- Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.JAMA network open · 2019 · on this mapPooled it
- Effects of Non-statin Lipid-Modifying Agents on Cardiovascular Morbidity and Mortality Among Statin-Treated Patients: A Systematic Review and Network Meta-Analysis.Frontiers in pharmacology · 2019Pooled it
- Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.The Cochrane database of systematic reviews · 2018 · on this mapPooled it
- Statins for primary prevention of venous thromboembolism.The Cochrane database of systematic reviews · 2014Pooled it
- Longitudinal Magnetic Resonance Imaging-Based Superficial Femoral Artery Velocity Measurements in Diabetic and Nondiabetic Patients With Peripheral Artery Disease.Topics in magnetic resonance imaging : TMRI · 2023Trial
- Comparison of Longitudinal Skeletal Thigh Muscle Findings With Magnetic Resonance Imaging in Patients With Peripheral Artery Disease With-Versus-Without Diabetes Mellitus.The American journal of cardiology · 2022Trial
- Magnetic Resonance Venous Volume Measurements in Peripheral Artery Disease (from ELIMIT).The American journal of cardiology · 2016Trial
- Enrollment of Historically Underrepresented Groups in Peripheral Arterial Disease Trials: A Systematic Review.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Review
- Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal transduction and targeted therapy · 2024Review
- Magnetic resonance imaging based superficial femoral artery velocity measurements in peripheral artery disease.Magnetic resonance imaging · 2022Article
- The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases.Aging and disease · 2021Article
- Statins and Peripheral Arterial Disease: A Narrative Review.Frontiers in cardiovascular medicine · 2021Review
- Magnetic resonance imaging based modeling of microvascular perfusion in patients with peripheral artery disease.Journal of biomechanics · 2019Article
- Patient-Specific Flow Descriptors and Normalized wall index in Peripheral Artery Disease: a Preliminary Study.Computer methods in biomechanics and biomedical engineering. Imaging & visualization · 2018Article
- Calf muscle perfusion as measured with magnetic resonance imaging to assess peripheral arterial disease.Medical & biological engineering & computing · 2016Article
- Magnetic resonance imaging-based computational modelling of blood flow and nanomedicine deposition in patients with peripheral arterial disease.Journal of the Royal Society, Interface · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Funding
Abstract
methodsA total of 102 patients were randomized to either mono-therapy with simvastatin (40 mg daily) or triple-therapy with simvastatin (40 mg daily), extended-release niacin (1500 mg daily), and ezetimibe (10 mg daily). MRI was performed at baseline and 6, 12, and 24 months. SFA wall, lumen, and total vessel volumes were quantified. MRI-derived SFA parameters and lipids were analyzed with multilevel models and nonparametric tests, respectively.
resultsBaseline characteristics did not differ between mono and triple-therapy groups, except for ethnicity (p = 0.02). SFA wall, lumen, and total vessel volumes increased non-significantly for both groups between baseline and 24-months. Non-high-density lipoprotein cholesterol was significantly reduced at 12 months with triple-therapy compared with mono-therapy (p = 0.01).
conclusionNo significant differences were observed between mono-therapy using simvastatin and triple-therapy with simvastatin, extended-release niacin, and ezetimibe for 24-month changes in SFA wall, lumen, and total vessel volumes. CLINICAL TRIAL REGISTRATION INFORMATION: NCT00687076; Link: http://clinicaltrials.gov/ct2/show/NCT00687076.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.